Volume 6, Issue 4 (Winter 2024)
Iran J Health Insur 2024, 6(4): 288-299 |
Back to browse issues page
Ethics code: IR.TUMS.REC.1401.006
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nourizadeh Tehrani P, Alipanah Dolatabad M, Daroudi R. Economic Evaluation of Molnopyravir, Paxlovid and Fluvoxamine in Treatment of COVID-19 Patients in Iran. Iran J Health Insur 2024; 6 (4) :288-299
URL: http://journal.ihio.gov.ir/article-1-300-en.html
URL: http://journal.ihio.gov.ir/article-1-300-en.html
1- Department of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2- Department of Health Services Management, School of Management and Health Informatics, Iran University of Medical Sciences, Tehran, Iran
3- Department of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran , rdaroudi@yahoo.com
2- Department of Health Services Management, School of Management and Health Informatics, Iran University of Medical Sciences, Tehran, Iran
3- Department of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran , rdaroudi@yahoo.com
Abstract: (191 Views)
Introduction: Various medications for the treatment of coronavirus disease 2019 (COVID-19) have been introduced in outpatient and inpatient wards. Three of the referees are Nirmatrelvir/ritonavir (Paxlovid), Molnupiravir and Fluvoxamine. The aim of this study was to investigate the cost-effectiveness of these drugs in treatment of patients with mild to moderate COVID-19 in Iran.
Methods: The present study was an economic evaluation study with the aim of investigating the cost-effectiveness of drugs. A two-part decision analysis model of decision tree model and Markov model was used to investigate cost-effectiveness. The study parameters included hospitalization, death rate, drugs, quality of life and treatment costs in 2012.
Results: The results showed that standard treatment had higher cost and lower average outcome (QALY) compared to the average fluvoxamine. Molnopyravir had a higher average cost (202.205.422 vs. 155.243.881) and lower QALY (4.352 vs. 4.363). The average cost of Paxlovid was higher (133.712.604 Rials vs. 3.328.029) and the average QALY (0.969 vs. 0.966). The cost-effectiveness ratio of pexelloids compared with fluvoxamine was 302.781.040.50 Rials. If the cost of the course of treatment with pexelloids is less than 2.108.425 Rials, this drug will be cost-effective.
Conclusion: It can be concluded that the use of paxlovid and molnopyravir in the treatment of COVID-19 patients in the mild to moderate stage who are at high risk for disease progression is not cost-effective at current prices. In the case of fluvoxamine, although the drug is cost-effective based on the available evidence, there is a lot of uncertainty about its effectiveness.
Methods: The present study was an economic evaluation study with the aim of investigating the cost-effectiveness of drugs. A two-part decision analysis model of decision tree model and Markov model was used to investigate cost-effectiveness. The study parameters included hospitalization, death rate, drugs, quality of life and treatment costs in 2012.
Results: The results showed that standard treatment had higher cost and lower average outcome (QALY) compared to the average fluvoxamine. Molnopyravir had a higher average cost (202.205.422 vs. 155.243.881) and lower QALY (4.352 vs. 4.363). The average cost of Paxlovid was higher (133.712.604 Rials vs. 3.328.029) and the average QALY (0.969 vs. 0.966). The cost-effectiveness ratio of pexelloids compared with fluvoxamine was 302.781.040.50 Rials. If the cost of the course of treatment with pexelloids is less than 2.108.425 Rials, this drug will be cost-effective.
Conclusion: It can be concluded that the use of paxlovid and molnopyravir in the treatment of COVID-19 patients in the mild to moderate stage who are at high risk for disease progression is not cost-effective at current prices. In the case of fluvoxamine, although the drug is cost-effective based on the available evidence, there is a lot of uncertainty about its effectiveness.
Type of Study: Research |
Subject:
Special
Received: 2023/11/25 | Revised: 2024/04/20 | Accepted: 2024/02/14 | ePublished: 2024/03/12
Received: 2023/11/25 | Revised: 2024/04/20 | Accepted: 2024/02/14 | ePublished: 2024/03/12
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
